Kanabo Group jumps as it signs agreement with Pure Origin

Francesca Morgan
Vox Newswire
10:45, 20th May 2021

Kanabo Group (KNB FOLLOW) has signed an agreement with Pure Origin and its affiliates ("Pure Origin"), to utilise their significant expertise in best practices for EU GMP manufacturing. 

The Group, which distributes cannabis-derived products for medical patients, explained how Good Manufacturing Practices systems are created and authorised by the government to regulate production, verification and validation of drugs, food and/or medical devices, ensuring that finished products are effective and safe for market distribution. 

Under the agreement Pure Origin and its affiliates will manufacture, package and supply Kanabo's CBD wellness product line from their EU GMP manufacturing facility in Wales.  

As part of the deal, Kanabo informed investors that it can ensure consumers ‘will continue to receive the highest quality of consistent, traceable, safe, and compliant products.’ 

Pure Origin and Kanabo will also establish a dedicated production line for the VapePod's CBD Wellness formulas that will use Kanabo's equipment, production protocols and IP.  

Shares in Kanabo Group were trading 6.38% higher this morning at 20p following the news. 

KNB price chart

Under the deal, Kanabo will supply raw materials to Pure Origin for the preparation of CBD formulations and final packaging. The current production line will have an initial capacity of 44,000 units a month with the ability to further increase production when necessary. 

This new agreement marks the end of the period of pilot sales which commenced upon the company’s admission to the LSE and is the prelude to a full product launch internationally. 

The pilot sales, which has lasted a period of three months, has provided several important performance measures in relation to the sale of Kanabo's retail CBD products in the UK.  

In particular, the outcome of the pilot has formed the second phase of Kanabo's strategy to increase revenue from the sale of CBD products, and Kanabo's future long-term strategy involves continued research and development activities to develop a range of Unlicensed Medical Cannabis Oils, which will be sold as unlicensed medical products, it highlighted. 

For more news and updates on  Kanabo Group


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles